| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
Polyporusterone A targets oxidative stress pathways by inhibiting free radical-induced erythrocyte cleavage (hemolysis). Its hepatoprotective and antioxidant activities are attributed to its ability to modulate oxidative stress and cell signaling pathways. The compound shows potential anticancer and anti-inflammatory properties through modulation of oxidative stress and cell signaling pathways. As a triterpene carboxylic acid, it may interact with various cellular targets involved in liver protection, inflammation, and cell survival.
|
|---|---|
| ln Vitro |
In vitro, Polyporusterone A inhibits free radical-induced lysis of red blood cells (hemolysis), demonstrating potent antioxidant activity. It exhibits hepatoprotective activity in cell-based models, protecting liver cells from oxidative damage. The compound shows potential anticancer and anti-inflammatory properties. Its ability to inhibit hemolysis suggests membrane-stabilizing effects that may contribute to its overall cytoprotective profile. Specific IC50 values are not detailed in the available literature.
|
| ln Vivo |
Specific in vivo data for Polyporusterone A are limited. The compound is used in studies of hair regeneration and psoriasis, suggesting potential for in vivo efficacy in these areas. Its hepatoprotective activity suggests potential for in vivo studies in liver injury models. The compound's diuretic activity also indicates potential applications in renal research. However, specific published in vivo protocols for this compound are not detailed in the available literature. Further in vivo studies are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
The antioxidant activity of Polyporusterone A is assessed using in vitro assays. For hemolysis inhibition, red blood cells are isolated from blood samples and suspended in buffer. The cells are treated with Polyporusterone A at various concentrations and then exposed to free radical-generating systems (e.g., AAPH or H₂O₂). The degree of hemolysis is measured spectrophotometrically at 540 nm, and the percentage inhibition is calculated compared to control samples without the compound.
|
| Cell Assay |
For cellular studies, hepatocyte cell lines (e.g., HepG2) or other relevant cell types are cultured in appropriate media. Cells are treated with Polyporusterone A at various concentrations (e.g., 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or similar assays. Oxidative stress is induced using H₂O₂ or other pro-oxidants, and cell protection is measured. ROS levels are measured using DCFH-DA. The compound is typically dissolved in DMSO and diluted in culture media, with a final DMSO concentration ≤0.1%.
|
| Animal Protocol |
In vivo studies for Polyporusterone A would be conducted in appropriate animal models. For hepatoprotection studies, mice or rats would be treated with hepatotoxic agents (e.g., CCl₄, acetaminophen) followed by Polyporusterone A administration via oral gavage or intraperitoneal injection. Liver injury would be assessed by measuring serum ALT and AST levels, liver histopathology, and markers of oxidative stress. For hair regeneration studies, appropriate models would be used. For psoriasis studies, imiquimod-induced or other psoriasis models would be employed.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Polyporusterone A are not reported. The compound has a molecular weight of 478.66 g/mol. As a triterpene carboxylic acid, it is expected to have moderate lipophilicity. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, oral bioavailability, and tissue distribution in animal models. The compound is typically stored as a powder at -20°C and protected from light.
|
| Toxicity/Toxicokinetics |
As a natural product from Polyporus umbellatus, which has traditional medicinal uses, Polyporusterone A is generally considered to have a moderate safety profile. Its antioxidant and hepatoprotective properties suggest potential benefits rather than toxicity. However, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound should be handled with appropriate safety precautions in laboratory settings.
|
| References | |
| Additional Infomation |
Polyporus umbellatus A is a steroidal compound. It has been reported that polyporus umbellatus contains polyporus umbellatus A, and relevant data are available for reference.
Polyporusterone A is a triterpene carboxylic acid from Polyporus umbellatus that inhibits free radical-induced hemolysis and exhibits hepatoprotective, antioxidant, diuretic, anticancer, and anti-inflammatory activities. It is used in studies of hair regeneration and psoriasis. No clinical trials or regulatory approvals exist. For research use only. |
| Molecular Formula |
C28H46O6
|
|---|---|
| Molecular Weight |
478.661249637604
|
| Exact Mass |
478.329
|
| CAS # |
141360-88-5
|
| PubChem CID |
10814524
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
854
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O[C@H]1C[C@@]2(C)[C@H](C(=O)C=C3[C@@H]2CC[C@@]2(C)[C@@]3(O)CC[C@@H]2[C@](O)(C)[C@H](O)C[C@H](C)C(C)C)C[C@H]1O
|
| InChi Key |
KQBCIGPPRFLKLS-UMQUCXETSA-N
|
| InChi Code |
InChI=1S/C28H46O6/c1-15(2)16(3)11-24(32)27(6,33)23-8-10-28(34)18-12-20(29)19-13-21(30)22(31)14-25(19,4)17(18)7-9-26(23,28)5/h12,15-17,19,21-24,30-34H,7-11,13-14H2,1-6H3/t16-,17-,19-,21+,22-,23-,24+,25+,26+,27+,28+/m0/s1
|
| Chemical Name |
(2S,3R,5R,9R,10R,13R,14S,17S)-17-[(2R,3R,5S)-2,3-dihydroxy-5,6-dimethylheptan-2-yl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0892 mL | 10.4458 mL | 20.8917 mL | |
| 5 mM | 0.4178 mL | 2.0892 mL | 4.1783 mL | |
| 10 mM | 0.2089 mL | 1.0446 mL | 2.0892 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
